종목/QGEN
Qiagen N.V.
키아젠(Qiagen N.V., 이하 키아젠)은 생물학적 샘플을 분자적 인사이트로 전환하는 '샘플 투 인사이트' 솔루션을 제공하는 진단·연구용 시약·기기 회사입니다. 핵심 사업은 핵산( DNA/RNA) 안정화·추출용 키트와 실리카 멤브레인·마그네틱 비드 기반 정제기술, 수동·자동 처리 장비 등 샘플 전처리와 정제용 소모품·장비이며, PCR·qPCR·디지털 PCR 등 분자검사용 시약과 기기, NGS(차세대염기서열)용 패널·라이브러리 전처리 키트, DNA 메틸화 분석 및 전장유전체 증폭 솔루션도 포함합니다. 또한 결핵용 인터페론 감마 방출 검사 등 면역반응 소모품, 이식 후 모니터링·바이러스 부하·종양·산전·성병(HPV 포함) 검사 등 임상진단용 어세이와 포렌식·인간식별용 어세이를 제공하며, 바이오인포매틱스 및 SaaS 형태의 소프트웨어도 제공합니다. 주요 경쟁사는 분자진단·시약·NGS 분야의 글로벌 기업들이며, 한국 투자자는 제품군이 샘플 전처리부터 분석·소프트웨어까지 광범위하게 수직통합되어 있다는 점과 분자진단·연구 수요에 연동된 포트폴리오 구성을 유의할 필요가 있습니다.
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
| 발표일 | 분기 | EPS 예상 | EPS 실제 | Surprise | 매출 실제 | 발표 직후 반응 |
|---|---|---|---|---|---|---|
| 5월 7일 (목) | 2026 Q1 | $0.55 | $0.54 | −2.1% | $492M | — |
| 100% (4/4) |
| UNH | 유나이티드헬스 | 389B | +8.9% | 75% (3/4) |
| MRK | 머크 | 318B | +16.0% | 100% (4/4) |